New hope for lung cancer relapse: drug combo trial launches

NCT ID NCT06680050

Recruiting now Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving radiotherapy followed by two drugs—durvalumab (an immunotherapy) and ceralasertib (a targeted therapy)—can help people with stage III non-small cell lung cancer whose cancer has returned in the chest after standard treatment. The study will enroll 21 adults and measure safety, tumor shrinkage, and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug) and ceralasertib (a targeted drug)
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer that has returned after initial therapy.
What could go wrong: This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The combination of drugs may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

ASST Grande Ospedale Metropolitano Niguarda
RECRUITING

Milan, Italy
ASST degli Spedali Civili di Brescia
NOT_YET_RECRUITING

Brescia, Italy
Azienda Ospedaliero - Universitaria di Parma
NOT_YET_RECRUITING

Parma, Italy
Azienda Ospedaliero Universitaria Careggi
RECRUITING

Florence, Italy
Azienda ospedaliera di Padova
NOT_YET_RECRUITING

Padova, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITING

Milan, Italy
IRCCS Ospedale Policlinico San Martino, Genova
RECRUITING

Genova, Italy
University Hospital Zurich
NOT_YET_RECRUITING

Zurich, Switzerland
University Hospital of Geneva
NOT_YET_RECRUITING

Geneva, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.